Yahoo Finance 4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), has sold 5,833 shares of the company on March 27, 2024, according to a recent SEC filing. The transaction was executed at a price of $35.04 per share, resulting in a total sale amount of $204,396.32.
4D Molecular Therapeutics Inc, a clinical-stage gene therapy company, is focused on the discovery and development of targeted and proprietary AAV gene therapy vectors and therapeutic products for use in patients with severe genetic diseases and cancer. The company's pioneering Therapeutic Vector Evolution platform allows for the creation of customized gene delivery vehicles to deliver genes to specific tissues in the body, potentially providing treatment for a wide range of diseases.
Over the past year, Scott Bizily has engaged in the sale of 21,236 shares of 4D Molecular Therapeutics Inc and has not made any purchases of the stock. The insider's recent sale contributes to a pattern observed over the last year, where insider transactions have predominantly been sales. In total, there has been 1 insider buy and 12 insider sells for the company within this period.
On the day of the sale, 4D Molecular Therapeutics Inc's shares were trading at $35.04, giving the company a market capitalization of $1.584 billion. The stock's price on that day was significantly higher than the GuruFocus Value (GF Value) of $16.58, indicating a price-to-GF-Value ratio of 2.11. This suggests that 4D Molecular Therapeutics Inc is significantly overvalued based on its GF Value.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also includes an adjustment factor based on the company's historical returns and growth, as well as future business performance estimates provided by Morningstar analysts.
The insider trend image above reflects the recent insider selling and buying activities at 4D Molecular Therapeutics Inc.
The GF Value image provides a visual representation of the stock's current valuation in comparison to its intrinsic value, as estimated by GuruFocus.
For more detailed information on insider transactions and the company's financial performance, investors and analysts are encouraged to review the full SEC filings and explore additional data on GuruFocus.com.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
